Insights to ligand binding to the monoamine transporters – from homology modeling to LeuBAT and dDAT

Understanding of drug binding to the human biogenic amine transporters is essential to explain the mechanism of action of these pharmaceuticals but more importantly to be able to develop new and improved compounds to be used in the treatment of depression or drug addiction. Until recently no high re...

Full description

Bibliographic Details
Main Authors: Heidi eKoldsø, Julie eGrouleff, Birgit eSchiøtt
Format: Article
Language:English
Published: Frontiers Media S.A. 2015-09-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fphar.2015.00208/full
id doaj-900a35a2798543f88fba737129b2cf15
record_format Article
spelling doaj-900a35a2798543f88fba737129b2cf152020-11-24T23:48:49ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122015-09-01610.3389/fphar.2015.00208159331Insights to ligand binding to the monoamine transporters – from homology modeling to LeuBAT and dDATHeidi eKoldsø0Julie eGrouleff1Birgit eSchiøtt2Department of Biochemistry, University of OxfordAarhus UniversityAarhus UniversityUnderstanding of drug binding to the human biogenic amine transporters is essential to explain the mechanism of action of these pharmaceuticals but more importantly to be able to develop new and improved compounds to be used in the treatment of depression or drug addiction. Until recently no high resolution structure was available of the biogenic amine transporters and homology modeling was a necessity. Various studies have revealed experimentally validated binding modes of numerous ligands to the biogenic amine transporters using homology modeling. Here we examine and discuss the similarities between the binding models of substrates, antidepressants, psychostimulants and anti-abuse drugs in homology models of the human biogenic amine transporters and the recently published crystal structures of the drosophila dopamine transporter and the engineered protein, LeuBAT. The comparison reveals that careful computational modeling combined with experimental data can be utilized to predict binding of molecules to proteins that agree very well with crystal structures.http://journal.frontiersin.org/Journal/10.3389/fphar.2015.00208/fullantidepressantserotonin transporterPsychostimulantsdopamine transporternorepinephrine transporterLeucine Transporters
collection DOAJ
language English
format Article
sources DOAJ
author Heidi eKoldsø
Julie eGrouleff
Birgit eSchiøtt
spellingShingle Heidi eKoldsø
Julie eGrouleff
Birgit eSchiøtt
Insights to ligand binding to the monoamine transporters – from homology modeling to LeuBAT and dDAT
Frontiers in Pharmacology
antidepressant
serotonin transporter
Psychostimulants
dopamine transporter
norepinephrine transporter
Leucine Transporters
author_facet Heidi eKoldsø
Julie eGrouleff
Birgit eSchiøtt
author_sort Heidi eKoldsø
title Insights to ligand binding to the monoamine transporters – from homology modeling to LeuBAT and dDAT
title_short Insights to ligand binding to the monoamine transporters – from homology modeling to LeuBAT and dDAT
title_full Insights to ligand binding to the monoamine transporters – from homology modeling to LeuBAT and dDAT
title_fullStr Insights to ligand binding to the monoamine transporters – from homology modeling to LeuBAT and dDAT
title_full_unstemmed Insights to ligand binding to the monoamine transporters – from homology modeling to LeuBAT and dDAT
title_sort insights to ligand binding to the monoamine transporters – from homology modeling to leubat and ddat
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2015-09-01
description Understanding of drug binding to the human biogenic amine transporters is essential to explain the mechanism of action of these pharmaceuticals but more importantly to be able to develop new and improved compounds to be used in the treatment of depression or drug addiction. Until recently no high resolution structure was available of the biogenic amine transporters and homology modeling was a necessity. Various studies have revealed experimentally validated binding modes of numerous ligands to the biogenic amine transporters using homology modeling. Here we examine and discuss the similarities between the binding models of substrates, antidepressants, psychostimulants and anti-abuse drugs in homology models of the human biogenic amine transporters and the recently published crystal structures of the drosophila dopamine transporter and the engineered protein, LeuBAT. The comparison reveals that careful computational modeling combined with experimental data can be utilized to predict binding of molecules to proteins that agree very well with crystal structures.
topic antidepressant
serotonin transporter
Psychostimulants
dopamine transporter
norepinephrine transporter
Leucine Transporters
url http://journal.frontiersin.org/Journal/10.3389/fphar.2015.00208/full
work_keys_str_mv AT heidiekoldsø insightstoligandbindingtothemonoaminetransportersfromhomologymodelingtoleubatandddat
AT julieegrouleff insightstoligandbindingtothemonoaminetransportersfromhomologymodelingtoleubatandddat
AT birgiteschiøtt insightstoligandbindingtothemonoaminetransportersfromhomologymodelingtoleubatandddat
_version_ 1725484365757022208